Gandawan, Tarhata M.

HRN: 13-93-29  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/18/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/18/2024
09/25/2024
IV
500
Q6
Age
Waiting Final Action 
09/18/2024
CIPROFLOXACIN 500MG (TAB)
09/18/2024
09/25/2024
PO
500
BID
Age
Waiting Final Action 
09/18/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
09/18/2024
09/18/2024
IV
4.5gm
LD
Sepsis
Waiting Final Action 
09/18/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/18/2024
09/25/2024
IV
500mg
Q6H
Sepsis
Waiting Final Action 
09/19/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
09/19/2024
09/26/2024
IV
4.5g
Q6hr
Sepsis
Waiting Final Action 
09/25/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
09/25/2024
10/09/2024
IV
4.5gms
Q8
CAP HR
Waiting Final Action 
09/25/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/25/2024
10/09/2024
IV
500mg
Q8
CAP HR
Waiting Final Action 
09/25/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
09/25/2024
10/02/2024
IV
4.5gms
Q6
CAP HR
Waiting Final Action 
09/25/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/25/2024
10/02/2024
IV
500mg
Q6
CAP HR
Waiting Final Action 
10/04/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/01/2024
10/11/2024
IV
2.25
Q12
CAP HR
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: